scholarly journals Natural Killer Cells Promote Early CD8 T Cell Responses against Cytomegalovirus

2007 ◽  
Vol 3 (8) ◽  
pp. e123 ◽  
Author(s):  
Scott H Robbins ◽  
Gilles Bessou ◽  
Amélie Cornillon ◽  
Nicolas Zucchini ◽  
Brigitte Rupp ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
T Cell Responses ◽  
Cd8 T Cell ◽  
Killer Cells ◽  
Cell Responses

scholarly journals Natural Killer Cells Activated by MHC Class ILow Targets Prime Dendritic Cells to Induce Protective CD8 T Cell Responses

Immunity ◽  
2003 ◽  
Vol 19 (4) ◽  
pp. 561-569 ◽  
Author(s):  
Ralph Mocikat ◽  
Heidi Braumüller ◽  
Alain Gumy ◽  
Oliver Egeter ◽  
Heike Ziegler ◽  
...  
Keyword(s):  
Dendritic Cells ◽  
T Cell ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
T Cell Responses ◽  
Cd8 T Cell ◽  
Killer Cells ◽  
Cell Responses

Natural killer cells regulate diverse T cell responses

2013 ◽  
Vol 34 (7) ◽  
pp. 342-349 ◽  
Author(s):  
Sarah Q. Crome ◽  
Philipp A. Lang ◽  
Karl S. Lang ◽  
Pamela S. Ohashi
Keyword(s):  
T Cell ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
T Cell Responses ◽  
Killer Cells ◽  
Cell Responses

scholarly journals Increased degranulation of natural killer cells during acute HCV correlates with the magnitude of virus-specific T cell responses

2010 ◽  
Vol 53 (5) ◽  
pp. 805-816 ◽  
Author(s):  
Sandy Pelletier ◽  
Christian Drouin ◽  
Nathalie Bédard ◽  
Salim I. Khakoo ◽  
Julie Bruneau ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
T Cell Responses ◽  
Killer Cells ◽  
Cell Responses ◽  
Acute Hcv

scholarly journals Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia — a randomized controlled trial.

2019 ◽  
Author(s):  
Lin Yun ◽  
Miao Zhuang ◽  
Wu Yue ◽  
Ge Fangfang ◽  
Wen Qingping
Keyword(s):  
T Cell ◽  
Postoperative Pain ◽  
Natural Killer Cells ◽  
Immune Function ◽  
Natural Killer ◽  
Low Dose ◽  
Cd8 T Cell ◽  
Killer Cells ◽  
Cell Ratio ◽  
Vas Scores

Abstract Background: Perioperative immune function plays an important role in the prognosis of patients. Several studies have indicated that low-dose opioid receptor blockers can improve immune function. Methods: Sixty-nine patients undergoing video-assisted thoracoscopic resection of the lung cancer were randomly assigned to either the naloxone group (n=35) or the non-naloxone group (n=34) for postoperative analgesia during the first 48 hours after the operation. Both groups received sufentanil and palonosetron via postoperative analgesia pump, while 0.05μg·kg-1·h-1 naloxone was added in naloxone group. The primary outcomes were the level of opioid growth factor（OGF）and immune function assessed by natural killer cells and CD4+/CD8+ T-cell ratio. Second outcomes were assessed by the intensity of postoperative pain, postoperative rescue analgesia dose, postoperative nausea and vomiting (PONV). Results: The level of OGF in the naloxone group increased significantly at 24 hours (p＜0.001) and 48 hours after the operation (P<0.01). The natural killer cells (P<0.05) and CD4+/CD8+ T-cell ratio (P<0.01) in the naloxone group increased significantly at 48 hours after the operation. The rest VAS scores were better with naloxone at 12 and 24 hours after operation（P<0.05）, and the coughing VAS scores were better with naloxone at 48 hours after the operation（P<0.05). The consumption of postoperative rescue analgesics in the naloxone group was lower (0.00（0.00-0.00）vs 25.00（0.00-62.50）），P<0.05). Postoperative nausea scores at 24 hours after operation decreased in naloxone group（0.00 (0.00-0.00) vs 1.00 (0.00-2.00), P < 0.01). Conclusion: Infusion of 0.05μg·kg-1·h-1 naloxone for patients undergoing sufentanil-controlled analgesia for postoperative pain can significantly increase the level of OGF, natural killer cells, and CD4+/CD8+ T-cell ratio compared with non-naloxone group，and postoperative pain intensity, request for rescue analgesics, and opioid-related side effects can also be reduced. Trial registration: The trial was registered at the Chinese Clinical Trial Registry on January 26, 2019（ChiCTR1900021043）. Keywords: Low-dose naloxone, Opioid growth factor, Immune function, Postoperative pain, nausea, vomiting

Abstract B037: Improved CD8+ T-cell recognition of neuroblastoma after innate immune attack by natural killer cells

2016 ◽  
Author(s):  
Lotte Spel ◽  
Jaap J. Boelens ◽  
Niek van Til ◽  
Dirk M. van der Steen ◽  
Nina J.G. Blokland ◽  
...  
Keyword(s):  
T Cell ◽  
Natural Killer Cells ◽  
Natural Killer ◽  
Cd8 T Cell ◽  
Innate Immune ◽  
Cell Recognition ◽  
Killer Cells ◽  
T Cell Recognition ◽  
Immune Attack

scholarly journals Effect of low dose naloxone on the immune system function of a patient undergoing video-assisted thoracoscopic resection of lung cancer with sufentanil controlled analgesia — a randomized controlled trial.

2019 ◽  
Author(s):  
Lin Yun ◽  
Miao Zhuang ◽  
Wu Yue ◽  
Ge Fangfang ◽  
Wen Qingping
Keyword(s):  
T Cell ◽  
Postoperative Pain ◽  
Natural Killer Cells ◽  
Immune Function ◽  
Natural Killer ◽  
Low Dose ◽  
Cd8 T Cell ◽  
Killer Cells ◽  
Cell Ratio ◽  
Vas Scores

Abstract Background : Perioperative immune function plays an important role in the prognosis of patients. Several studies have indicated that low-dose opioid receptor blockers can improve immune function. Methods: Sixty-nine patients undergoing video-assisted thoracoscopic resection of the lung cancer were randomly assigned to either the naloxone group (n=35) or the non-naloxone group (n=34) for postoperative analgesia during the first 48 hours after the operation. Both groups received sufentanil and palonosetron via postoperative analgesia pump, while 0.05μg·kg -1 ·h -1 naloxone was added in naloxone group. The primary outcomes were the level of opioid growth factor （OGF） and immune function assessed by natural killer cells and CD4 + /CD8 + T-cell ratio. Second outcomes were assessed by the intensity of postoperative pain, postoperative rescue analgesia dose, postoperative nausea and vomiting (PONV). Results: The level of OGF in the naloxone group increased significantly at 24 hours ( p ＜0.001) and 48 hours after the operation ( P <0.01). The natural killer cells ( P <0.05) and CD4 + /CD8 + T-cell ratio ( P <0.01) in the naloxone group increased significantly at 48 hours after the operation. The rest VAS scores were better with naloxone at 12 and 24 hours after operation（ P <0.05）, and the coughing VAS scores were better with naloxone at 48 hours after the operation（ P <0.05). The consumption of postoperative rescue analgesics in the naloxone group was lower (0.00（0.00-0.00）vs 25.00（0.00-62.50））， P <0.05). Postoperative nausea scores at 24 hours after operation decreased in naloxone group（0.00 (0.00-0.00) vs 1.00 (0.00-2.00), P < 0.01). Conclusion: Infusion of 0.05μg·kg -1 ·h -1 naloxone for patients undergoing sufentanil-controlled analgesia for postoperative pain can significantly increase the level of OGF, natural killer cells, and CD4+/CD8+ T-cell ratio compared with non-naloxone group ，and postoperative pain intensity, request for rescue analgesics, and opioid-related side effects can also be reduced. Trial registration: ChiCTR1900021043 on January 26, 2019. Keywords: Low-dose naloxone, Opioid growth factor, Immune function, Postoperative pain, nausea, vomiting

Sign in / Sign up

Export Citation Format

Share Document